New DOT Observed Collection Rule Takes Effect June 10, 2026: What Employers Must Know

The Department of Transportation published a final rule on May 11, 2026, amending its drug and alcohol testing procedures under 49 CFR Part 40. The rule — effective June 10, 2026 — resolves a practical gap in directly observed collection requirements that has existed since DOT authorized oral fluid testing in 2023, and it updates observer-matching terminology in response to Executive Order 14168.

For every DOT-regulated employer with drivers, pilots, mariners, pipeline workers, or transit employees subject to federal drug testing, this 30-day compliance window matters. Here is what the rule changes, why it exists, and what your Designated Employer Representative (DER) needs to do before the effective date.

Background: The Oral Fluid Testing Gap

In May 2023, DOT updated 49 CFR Part 40 to authorize oral fluid specimen testing as an alternative to urine collection for most DOT-mandated drug tests. That same rulemaking added a provision stating that when a directly observed urine collection is required but a same-sex observer cannot be found, the collector should switch to an oral fluid test — since oral fluid collections are inherently observed (the collector watches the employee provide the specimen).

The logic was sound. The implementation was not. As of May 2026, there are still no HHS-certified laboratories authorized to process oral fluid specimens for DOT-regulated testing. The 2023 rule effectively required something that could not happen, leaving collectors, DERs, and employers in a regulatory gray area when same-sex observer situations arose.

The May 11, 2026 final rule closes that gap.

What the Rule Changes

The final rule (Document 2026-09290, 91 FR 25507) makes two primary changes to 49 CFR Part 40:

1. Directly Observed Urine Collection as the Fallback

The rule amends § 40.67(g) to establish clear procedures when a directly observed collection is required but a same-sex observer is unavailable:

While oral fluid testing remains unavailable:

• The collector contacts the Designated Employer Representative (DER)
• The DER either arranges for a same-sex observer at the current site, or
• The DER directs the employee to a different collection site that can perform a directly observed urine collection
• Oral fluid testing is not required during this period

Once oral fluid testing becomes available:

• "Available" means at least two HHS-certified oral fluid laboratories are operational
• When that threshold is met, a directly observed oral fluid collection must be performed when a same-sex observer cannot be found for a urine test
• Employers may provide standing orders to collection sites specifying how to handle these situations under new § 40.65(d)

The 18-month grace period:

• After HHS certifies the second oral fluid laboratory and publishes a Federal Register notice, employers receive an 18-month transition window
• During this grace period, directly observed urine collections remain acceptable even in scenarios that would otherwise require oral fluid
• ODAPC will publish a separate Federal Register notice announcing start and end dates

2. Terminology Update: "Gender" Replaced with "Sex"

In compliance with Executive Order 14168, the rule replaces all references to "gender" with "sex (male or female)" in the directly observed collection provisions. This affects:

• § 40.67(g) and (h) — observer requirements for directly observed collections
• § 40.69(c) and (d) — monitored collection procedures
• § 40.145(h)(1)(ii) — MRO-directed observed collections

The practical effect: observers and monitors for directly observed urine collections must be of the same biological sex as the donor.

When Directly Observed Collections Are Required

Most DOT drug tests — pre-employment, random, and periodic — are not directly observed. The employee provides a specimen privately. Directly observed collections are required only in specific circumstances under 49 CFR § 40.67:

The employer must direct an observed collection when:

1. The laboratory reported the specimen as invalid and the MRO found no adequate medical explanation
2. The MRO cancelled an original positive, adulterated, or substituted result because the split specimen could not be tested
3. The laboratory reported a negative-dilute with creatinine between 2–5 mg/dL, and the MRO directed observation per § 40.197(b)(1)
4. A required observed collection was never conducted

The employer must also direct observed collection for:

• Every return-to-duty (RTD) test after a violation is resolved through the SAP process
• Every follow-up test in the post-RTD series (minimum 6 tests in 12 months per § 40.307)

The collector must initiate observation when:

• The DER has already directed it
• Materials or conduct indicate a tampering attempt
• Specimen temperature is out of range (below 90°F or above 100°F)
• The specimen appears to have been tampered with
• The test is for return-to-duty or follow-up

An employee who refuses a required directly observed collection is treated as a refusal to test — carrying the same consequences as a verified positive result.

What This Means for Employers

For most DOT-regulated employers, the June 10, 2026 rule does not require immediate operational changes. It formally re-establishes the procedure that was effectively in place before the 2023 oral fluid authorization created ambiguity. However, the rule creates specific compliance obligations that DERs and safety managers should address now.

Action Items Before June 10, 2026

1. Review and update DER standing orders. The new § 40.65(d) requires collectors to check for a standing order before contacting the DER when a directly observed collection cannot proceed as planned. If your organization has not issued standing orders to collection sites covering same-sex observer unavailability, now is the time to create them.

2. Update internal policy language. Replace any references to "gender" with "sex (male or female)" in your drug and alcohol testing policies, training materials, and collection site instructions to align with the updated regulatory text.

3. Brief collection site personnel. Ensure your contracted collection sites understand the new rule structure — particularly the distinction between current procedures (directly observed urine only) and future procedures (oral fluid once labs are certified).

4. Monitor the ODAPC oral fluid lab certification page. DOT maintains a list of HHS-certified oral fluid laboratories at transportation.gov/odapc/HHS_Certified_Oral_Fluid_Laboratories. When two labs appear on this list, the 18-month countdown begins.

5. Confirm your C/TPA is tracking the change. If you use a third-party consortium or program administrator, verify they are aware of the June 10 effective date and have updated their procedures accordingly. Organizations like BlueHive provide compliance guidance that tracks regulatory changes across the DOT testing landscape.

6. Document everything. If a directly observed collection situation arises and a same-sex observer is unavailable, document the DER's decision (arrange an observer or redirect to another site) in your testing records. Clear documentation protects you during DOT audits.

What Does NOT Change

• The drug testing panel remains the same (marijuana, cocaine, amphetamines, PCP, opioids)
• Random testing rates remain at 50% for drugs and 10% for alcohol
• Pre-employment, post-accident, and reasonable suspicion testing procedures are unchanged
• The FMCSA Clearinghouse reporting requirements are unaffected
• Fentanyl has not been added to the panel (that is a separate proposed rulemaking)

The Bigger Picture: Oral Fluid Testing Timeline

This rule exists because DOT's oral fluid testing infrastructure is still not operational. Understanding the timeline helps employers plan:

Milestone	Status
DOT authorizes oral fluid testing (49 CFR Part 40)	Finalized May 2023
HHS updates Mandatory Guidelines (adds fentanyl, oral fluid provisions)	Effective July 7, 2025
DOT proposes fentanyl addition to panel (NPRM)	Published September 2, 2025
First HHS-certified oral fluid lab	Pending — no confirmed date
Second HHS-certified oral fluid lab (triggers availability)	Pending
18-month employer grace period begins	After second lab certified
Oral fluid required in observed collection scenarios	After grace period ends

Until the oral fluid lab certification threshold is met, directly observed urine collections remain the standard for all scenarios covered by § 40.67. Employers should prepare for oral fluid but should not delay compliance with the current urine-based framework.

FAA-Specific Considerations

The rule includes an important carve-out for employers regulated under 14 CFR Part 120. If the first two HHS-certified oral fluid laboratories are located outside the United States, FAA-regulated employers subject to § 120.123(a) are not required to use them. For these employers, the grace period and oral fluid requirements do not take effect until two U.S.-based oral fluid laboratories are certified.

This distinction matters for aviation employers planning their testing program transitions.

Bottom Line

The June 10, 2026 rule is a narrow but important fix. It eliminates the regulatory impossibility created when DOT authorized oral fluid testing without operational lab infrastructure, and it ensures that directly observed collection procedures remain clear and enforceable. For employers, the immediate compliance lift is light — update your standing orders, revise your terminology, and confirm your service providers are current.

The larger transition — when oral fluid testing actually becomes available — will require more substantial preparation. But that clock has not started yet. Use this window to build the foundation so your program is ready when it does.

Sources

• DOT Final Rule: Procedures for Transportation Workplace Drug and Alcohol Testing Programs (91 FR 25507, May 11, 2026)
• 49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs
• DOT ODAPC: HHS-Certified Oral Fluid Laboratories
• Executive Order 14168: Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government
• DOT NPRM: Addition of Fentanyl to Drug Testing Panel (90 FR 42363, September 2, 2025)
• BlueHive: Ahead of the Curve — How 2025 Drug Screening Trends Impact Your Workplace